Rapport Therapeutics Announces Proposed Public Offerings of Common Stock and Convertible Notes

Rapport Therapeutics announced proposed underwritten public offerings of $200 million in common stock and $150 million in convertible senior notes due 2032. It also plans to grant underwriters 30-day options for up to an additional $30 million in stock and $22.5 million in notes to cover over-allotments, and to enter a concurrent private share-purchase agreement with an investor. The company said the capital raising will support development of its small-molecule precision medicine platform for neurological and psychiatric disorders.